Artwork
iconShare
 

Fetch error

Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on May 16, 2024 21:23 (1+ y ago)

What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.

Manage series 3574650
Content provided by Travere Therapeutics. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Travere Therapeutics or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
Listeners can expect to learn about: • The disease burden and underlying pathophysiology of IgA nephropathy, including the role of endothelin and angiotensin in disease progression • The current IgAN treatment landscape • The response to sparsentan, a dual endothelin angiotensin receptor antagonist, in patients with IgA nephropathy in the phase 3 PROTECT trial
  continue reading

One episode